Company profile: Theranostics Health
1.1 - Company Overview
Company description
- Provider of proteomics-based diagnostics and research services for drug development companies, developing diagnostic tests to enable personalized cancer therapies tailored to each patient’s tumor, utilizing Laser Capture Microdissection (LCM) and Reverse-phase Protein MicroArrays (RPMA) assays.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Theranostics Health
Mainz Biomed
HQ: Germany
Website
- Description: Provider of molecular genetic diagnostic solutions for early cancer detection, including ColoAlert, a non-invasive at-home PCR-based colorectal cancer screening test; eAArly DETECT, a multimodal test combining FIT, mRNA biomarkers and AI to differentiate CRC, advanced and non-advanced adenomas; PancAlert, an early-stage pancreatic cancer screening test in development; and ReconAAsense, an FDA PMA pivotal study for next-gen colorectal screening approval.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mainz Biomed company profile →
Quanticel
HQ: United States
Website
- Description: Provider of oncology drug discovery, leveraging a proprietary single-cell genomic analysis platform for human cancer to enable the discovery and development of breakthrough, first-in-class cancer therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quanticel company profile →
Five Prime Therapeutics
HQ: United States
Website
- Description: Provider of cancer treatment biotechnology, discovering and developing novel therapeutic proteins and antibodies by systematically screening all relevant human proteins to find the best for each clinical indication, enabled by its ProScreen Engine for rapid production and screening.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Five Prime Therapeutics company profile →
Advanced Accelerator Applications
HQ: France
Website
- Description: Provider of targeted radioligand therapies and precision imaging radioligands, offering LUTATHERA: a radioligand therapy using lutetium Lu 177 dotatate for treating tumors; PLUVICTO: a therapeutic radioligand containing lutetium Lu 177 vipivotide tetraxetan; diagnostic PET imaging kits NETSPOT, LOCAMETZ, and SOMAKIT TOC; and LysaKare to reduce renal radiation exposure during peptide-receptor radionuclide therapy with LUTATHERA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advanced Accelerator Applications company profile →
Lava Therapeutics
HQ: The Netherlands
Website
- Description: Provider of a bispecific antibody platform engaging gamma-delta (Vγ9Vδ2) T cells for treatment of hematological and solid cancers. Offers the Gammabody® platform to generate T cell engagers targeting tumor-associated antigens, and drug candidates LAVA-051 for hematologic malignancies and solid tumors, and LAVA-1207 for metastatic castration-resistant prostate cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lava Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Theranostics Health
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Theranostics Health
2.2 - Growth funds investing in similar companies to Theranostics Health
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Theranostics Health
4.2 - Public trading comparable groups for Theranostics Health
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →